Guggenheim Upgrades Freenome (NASDAQ:FRNM) to “Strong-Buy”

by · The Markets Daily

Freenome (NASDAQ:FRNM – Get Free Report) was upgraded by research analysts at Guggenheim to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

A number of other equities analysts have also recently weighed in on the stock. TD Cowen initiated coverage on shares of Freenome in a research report on Tuesday. They issued a “buy” rating and a $17.00 price objective for the company. Jefferies Financial Group started coverage on Freenome in a research report on Monday. They set a “buy” rating and a $17.00 target price on the stock. Leerink Partners started coverage on Freenome in a research note on Friday, August 14th. They issued an “outperform” rating and a $18.00 price target on the stock. Finally, BTIG Research initiated coverage on Freenome in a report on Monday. They issued a “buy” rating and a $17.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating and three have issued a Buy rating to the company’s stock. According to data from MarketBeat.com, Freenome presently has an average rating of “Buy” and an average price target of $18.00.

Read Our Latest Research Report on FRNM

Freenome Stock Down 0.9%

FRNM opened at $13.51 on Thursday. Freenome has a twelve month low of $9.97 and a twelve month high of $14.26.

Freenome Company Profile

(Get Free Report)

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.

Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.

Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.

Further Reading